Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV‐2 infection in children

Liu et al., Liver International, doi:10.1111/liv.15660

Jun 2023

Retrospective 280 Chinese families with children previously seen in a liver clinic assessing whether ursodeoxycholic acid (UDCA) reduced SARS-CoV-2 infection risk. Among infected families, the study found no significant difference in confirmed or suspected SARS-CoV-2 infections between children taking UDCA (80.9%) and those not taking it (77.6%) (p=0.843).

Important missing comments or errors? Let us know.

risk of case, 2.1% higher, RR 1.02, p = 0.88, treatment 95 of 146 (65.1%), control 51 of 80 (63.7%), confirmed.

risk of case, 4.3% higher, RR 1.04, p = 0.61, treatment 118 of 146 (80.8%), control 62 of 80 (77.5%), confirmed + suspected.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Liu et al., 29 Jun 2023, retrospective, China, peer-reviewed, survey, 2 authors.

This Paper UDCA All

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0